Apremilast ESTEEM Program Meets Primary and Major Secondary Endpoint...
Celgene International Sarl, a subsidiary of Celgene Corporation , today announced that statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving apremilast 30 mg BID monotherapy in both the ESTEEM 1 & 2 phase III studies.
Join the discussion below, or Read more at PR-inside.com.
Since: Sep 12
#1 Jan 7, 2013
As study found that 10 to 30 percent of psoriasis patient develop psoriatic arthritis, but there may some precautions to avoid these as it causes joint pain, joint stiffness and swelling.
#2 Jan 15, 2013
To learn more about Apremilast, check out http://www.rxwiki.com/apremilast
Add your comments below
|Republican health care plan unveiled: Cut Medic...||39 min||BHM5267||28|
|Which GOP senators have concerns with the healt...||1 hr||Denizen_Kate||19|
|GOP governors don't see 'Obamacare' going away (Oct '14)||1 hr||Medicaid is American||217|
|NEW Dirty Ki...K (Sep '16)||2 hr||Anon||22|
|Nine questions we have about the Senate health ...||9 hr||KillCommies||2|
|Flu vaccine ineffective for people 65 and older...||14 hr||VACCINES MAIM KILL||1|
|CDC panel again advises against FluMist||14 hr||VACCINES MAIM KILL||1|
|Nudity at doctor's office (Mar '07)||Wed||David||176|
Find what you want!
Search Health Forum Now
Copyright © 2017 Topix LLC